AU753458B2 - Fibrinogen-converting enzyme hybrids - Google Patents

Fibrinogen-converting enzyme hybrids Download PDF

Info

Publication number
AU753458B2
AU753458B2 AU19058/99A AU1905899A AU753458B2 AU 753458 B2 AU753458 B2 AU 753458B2 AU 19058/99 A AU19058/99 A AU 19058/99A AU 1905899 A AU1905899 A AU 1905899A AU 753458 B2 AU753458 B2 AU 753458B2
Authority
AU
Australia
Prior art keywords
polypeptide chain
thr
protein
ser
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU19058/99A
Other versions
AU1905899A (en
Inventor
Stewart A. Cederholm-Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AU1905899A publication Critical patent/AU1905899A/en
Application granted granted Critical
Publication of AU753458B2 publication Critical patent/AU753458B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6418Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals from snakes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Description

WO 99/29838 PCT/US98/26086 WO 9929838PCT/JSQR/6086 -1- FIBRINOGEN-CONVERTING ENZYME HYBRIDS The present invention is directed to multidomain proteins made up of a first polypeptide that is a fibrinogen-converting enzyme or a snake venom-derived proteinase and a second polypeptide that is a member of a binding pair, where the other member of the binding pair can be used to remove the fusion protein from a fibrin preparation that was formed through the action of the converting enzyme. The invention is further directed to recombinant methods of forming the multidomain protein, to nucleic acids and vectors used in such methods, and to methods of forming fibrin using the fusion protein.
The invention further provides a fusion protein between a fibrinogen-converting enzyme and a polypeptide designed to facilitate covalent attachment of one member of a binding pair. Also, the invention provides for an aggregate of the first polypeptide which is covalently linked to a member of a binding pair and the second polypeptide which binds to the first by way of its binding the member of a binding pair.
"Fibrin" sealants are widely used to reduce bleeding in surgery and to seal blood vessels and tissues that have been dissected either in surgery or through wounding. The term "fibrin" can be viewed as a misnomer in this context since historically "fibrin" sealants have been delivered as a material containing the precursor of fibrin, namely fibrinogen. In such sealants, fibrinogen material has been co-delivered at the site to be sealed with a proteinase enzyme that converts the fibrinogen to fibrin. Once a sufficient amount of fibrin is formed from the fibrinogen, the fibrin spontaneously polymerizes into a fibrin polymer which when sufficient polymer is assembled forms a fibrin clot.
Generally, the conversion enzyme has been bovine-derived thrombin. Recently, however, an effective sealant has been described that delivers fibrin, in a form that is prevented from polymerizating, to the site that is to be sealed. At the site, the polymerization prevention conditions are reversed, and an effective clot forms. See, Edwardson et al., European Patent Application No. EP 592,242. As described in EP 592,242, the fibrin in the sealant can be formed by contacting fibrinogen with a fibrinogen converting enzyme that is bound to a solid support. The solid support allows for the removal of the converting enzyme from the sealant.
One of the particular advantages of this fibrin sealant of EP 592,242 is that the sealant can be an autologous sealant that is rapidly prepared from a small amount of a patient's blood only minutes before surgery, and this preparation can be done using standard laboratory equipment. Processes for deriving the fibrinogen material of prior art sealants are much more demanding and more difficult to automate.
Specialized tools for preparing fribrin have also recently been described, and these tools allow an autologous sealant to be prepared from a patient in a rapid, highly reproducible, highly reliable, and highly safe manner. See, Holm, "Centrifuge Reagent Delivery System", WO 96/16713, Holm et al., "Method and Device for Separating Fibrin I from Blood Plasma", WO 96/16714 and Holm, "Centrifuge with Annular Filter", WO 96/16715.
The present invention provides additional means to remove the fibrinogen converting enzyme from the fibrin sealant preparation. In one aspect, the invention provides a fusion protein comprising the converting enzyme and another polypeptide that can be used to bind the fusion protein to a solid support after the converting enzyme has been used to form fibrin from fibrinogen. In another aspect, the invention provides a fusion protein comprising the converting enzyme and another polypeptide that can be used to covalently attach binding moieties. In yet another aspect, the converting enzyme and the other polypeptide are aggregated by means of the other polypeptide binding to an member of a binding pair which is covalently linked to the converting enzyme.
20 The above discussion of documents, acts, materials, devices, articles and the like is included in this specification solely for the purposes of providing a context for the present invention. It is not suggested or represented that any or all of these matters formed part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed in Australia before the priority date of each claim of this application.
Summary of the Invention In a first embodiment, the invention provides a multidomain protein comprising: a first polypeptide chain comprising a fibrinogen-converting enzyme; and a second polypeptide chain comprising an avidin or streptavidin S: 30 polypeptide effective to bind biotin; wherein the first polypeptide chain and second polypeptide chain are part of a continuous polypeptide chain.
In another embodiment of the invention the multidomain protein is a recombinant fusion protein. The invention also relates to nucleic acids which encode these recombinant fusion proteins and to vectors comprising these nucleic acids and to cells comprising these vectors.
The invention also relates to a method of producing recombinant fusion proteins comprising the steps of growing the cell comprising the vector in a culture medium and recovering from the cell or the culture medium the fusion protein.
The invention also relates to a method of preparing a fibrin composition comprising contacting a composition comprising fibrinogen with a multidomain protein of the present invention.
Definitions alpha, beta, first, second: Terms such as "first", "second", "alpha" and "beta" are used herein as arbitrary names to help distinguish recitals of similar elements.
bifunctional linkage groups: A bifunctional linkage group is a molecule having two sites for attaching to a protein or polypeptide. Preferred bifunctional linkage groups are polypeptides of from one to about 3 amino acids, preferably of from one to about 30 amino acids. Additionally, preferred bifunctional linkage groups can be crosslinking reagents, such as for example reagents having two reactive moieties such as succinimidyl esters, maleimides, iodoactyl groups and 20 nitrophenyl groups.
comprising: Throughout the description and claims of this specification, the word "comprise" and variations of the word, such as "comprising" and "comprises", is not intended to exclude other additives, components, integers or steps.
direct bonds: Direct bonds between two protein or polypeptides are bonds that link a nitrogen, carbon, oxygen or sulfur from one protein or polypeptide to a nitrogen, carbon, oxygen or sulfur from the other protein or polypeptide.
fibrinogen-converting enzyme: A fibrinogen-converting enzyme is a substance that catalyses a conversion of fibrinogen to a derivative that 30 spontaneously polymerises noncovalently to form fibrin polymer. Generally, the derivative will be fibrin I (desAA-fibrin), fibrin II (desAA-desBB-fibrin) or desBBfibrin.
S high affinity binding: High affinity binding between a first substance and a Z second substance is binding of sufficient avidity to allow for the first or second substance to be used as an affinity ligand for the isolation of the other substance. Typically, high affinity binding is reflected in an association constant of about 105 M- 1 or more, preferably 106 M- 1 or more, preferably 106 M 1 or more or more preferably 10 7
M-
1 or more.
monomeric fibrin: Monomeric fibrin is fibrin that has been prevented from polymerisation so that, for a solution form of a fibrin composition, when examined by such techniques as ultracentrifugation or gel filtration substantially all of the fibrin chain molecules in the composition behave as the nonpolymerized hexamers (C2p272). The phrase "substantially all" in this context means at least about 80% of the fibrin chain molecules, preferably at least about 90% more preferably at least about 95%. For solid forms, the monomeric form in some instances will be indicated by the fact that the solid was formed from a solution form of monomeric fibrin monomer by lyophilization or another dehydration method. If necessary, more involved analytical techniques can be applied to ascertain if the fibrin hexamers are not aggregated with polymerforming non-covalent bonds of type and strength involved in the formation of fibrin clots. Solid forms can include suspended solids within a liquid in which the fibrin is not soluble, such as a suspension in acetone.
spontaneously polymerises noncovalently to form fibrin polymer. Generally, the derivative will be fibrin I (desAA-fibrin), fibrin II (desAA-desBB-fibrin) or desBBfibrin.
high affinity binding: High affinity binding between a first substance and a second substance is binding of sufficient avidity to allow for the first or second substance to be used as an affinity ligand for the isolation of the other substance. Typically, high affinity binding is reflected in an association constant of about 10 5
M
1 or more, preferably 106 M- 1 or more, preferably 106 M 1 or more or more preferably 10 7
M-
1 or more.
monomeric fibrin: Monomeric fibrin is fibrin that has been prevented from polymerisation so that, for a solution form of a fibrin composition, when examined by such techniques as ultracentrifugation or gel filtration substantially all of the fibrin chain molecules in the composition behave as the nonpolymerized hexamers (C213272). The phrase "substantially all" in this context means at least about 80% of the fibrin chain molecules, preferably at least about 90% more preferably at least about 95%. For solid forms, the monomeric form in some instances will be indicated by the fact that the solid was formed from a solution form of monomeric fibrin monomer by lyophilization or another :dehydration method. If necessary, more involved analytical techniques can be 20 applied to ascertain if the fibrin hexamers are not aggregated with polymerforming non-covalent bonds of type and strength involved in the formation of fibrin clots. Solid forms can include suspended solids within a liquid in which the fibrin is not soluble, such as a suspension in acetone.
*oo N:\lRN\617493\retypedspeci7-6-02.doc WO 99/29838 PCT/US98/26086 -6peptide or polypeptide: The term "polypeptide" as used herein includes shorter polypeptides such as those often referred to a "peptides," for instance polypeptides of less than about 100 amino acid residues.
recombinant protein: A recombinant protein is a protein in a form or a protein expressed in a cell in which it would not be found but for the cell or organism that expresses the recombinant protein, or an ancestor of that cell or organism, having been transformed by the introduction of extrinsic nucleic acid material.
snake venom-derived proteinase: A snake venom-derived proteinase is a proteinase found in snake venom, a proteinase prepared from snake venom, a recombinant proteinase prepared from a cDNA for a snake venom proteinase or a portion of that cDNA which recombinant proteinase retains the proteolytic activity of the snake venom proteinase of the cDNA, a synthetically prepared snake venom proteinase or a portion of any of the foregoing that retains the proteolytic activity of the parent molecule.
Detailed Description Enzyme-to-Binding Polypeptide Fusion Protein The fibrinogen-converting enzyme is preferably batroxobin a proteinase from the snake venom of snakes of the genus Bothrops. Other proteinases of appropriate specificity can also be used. Snake venom proteinases are particularly suitable, including without limitation the venom enzymes from Agkistrodon acutus, Agkistrodon ancrod, Agkistrodon bilineatus, Agkistrodon contortrix contortrix, Agkistrodon halyspallas, Agkistrodon (Calloselasma) rhodostoma, Bothrops asper, Bothrops atrox, Bothrops insularis, Bothrops jararaca, Bothrops Moojeni, Lachesis muta muta, Crotalus adamanteus, Crotalus atrox, Crotalus durissus terrificus, Trimeresurusflavorviridis, Trimeresurus gramineus, Trimeresurus mucrosquamatus and Bitis gabonica. In one embodiment, enzymes from Bothrops are used.
The sequence for a fibrinogen-converting enzyme from Agkistrodon rhodostoma is described in Bach et al., W090/06362. Two sequences from Agkristrodon c. contortrix are described in Valenzuela et al., EP 0 323 722. The sequence of batroxobin (from Bothrops atrox moojeni), is described in Japanese Patent Application (Kokai) 2-124092.
Sequences for batroxobin, an enzyme from Trimeresurusflavorviridis, and an enzyme from Crotalus horridus are reported in Pirkle and Theodor, "Structure of Thrombin-like snake venom Proteinases", in Medical use of Snake Venom Proteins. Sequences from WO 99/29838 PCT/US98/26086 -7- Agkristrodon c. contortix, Russell's viper, Bothrops atrox moojeni and Trimeresurus flavoviridis are described in McMullen et al., Biochemistry 28:674-679, 1989.
Sequences for enzymes from Trimeresurus mucrosquamatus are available from the National Center for Biotechnology Information (NCBI, Bethesda, MD) under accession numbers 602596, 602598, 602600, 602602 and 602604. Sequence for an enzyme from Protobothrops mucrosquamatus is available from the NCBI under accession number 951152. Sequence for an enzyme from Agkistrodon ancrod (Malayan pit viper, also known as Calloselasma rhodostoma) is available from the SWISS-PROT protein database (accessible through the NCBI) under accession number P47797. Sequence for an enzyme from Bothrops atrox is available from the NCBI under accession number 211031 or Genbank under accession number J02684. Sequence for an enzyme from Bothropsjararaca is available from the PIR protein database (accessible through the NCBI) under accession number A54361. Sequences for enzymes from Russell's viper (Vipera Russelli) are available from the SWISS-PROT protein database (accessible through the NCBI) under accession numbers P18964 and P18965. Sequences for an enzyme from Trimeresurusflavoviridis is available from the SWISS-PROT protein database (accessible through the NCBI) under accession number P05620. Sequence for an enzyme from Crotalus atrox is available from the PIR protein database (accessible through the NCBI) under accession number A45655. Sequence for an enzyme from Agkistrodon bilineatus is available from the NCBI under accession number 211031.
Sequences for enzymes from Agkistrodon contortrix are available from the NCBI under accession numbers 603215 and 603217 and from GenBank (accessible through the NCBI) under accession numbers 106680, 106681, 106724 and 106751.
When the fibrinogen-converting enzyme is thrombin, generally the fusion protein of the invention will be formed by chemical methods. Recombinant methods must account for the proteolytic processing reactions required to generate thrombin from prothrombin, as was done by Falkner et al., International Patent Application W091/11519 ("Recombinantly Produced Blood Factors").
Snake-derived proteinases that convert prothrombin to thrombin are, for example, of use in large-scaled processes for producing thrombin, in methods for producing autologous thrombin. These methods are improved by the use of enzyme preparations that can be removed through the use of a binding-partner relationship. The snake-derived WO 99/29838 PCTIUS98/26086 -8prothrombin-converting enzyme is preferably from the venom of Ecchis carinatus. Other snake venom proteinases that are suitable, include without limitation the venom enzymes from Australian tiger snake and Akistrodon hallyspallys. For example, the sequence for a prothrombin activator (ecarin) from Kenyan Echis carinatus venom is described in Kawabata, Biochemistry 34: 1771-1778, 1995 (GenBank Accession No. D32212).
The polypeptide that is a member of a binding pair is preferably avidin or Streptavidin, which polypeptides each bind with high affinity to biotin. An amino acid sequence for avidin is described in Dayhoff, Atlas of Protein Sequence, Vol. 5, National Biomedical Research Foundation, Washington, DC, 1972 (see also, DeLange and Huang, J. Biol. Chem. 246: 698-709, 1971), and an amino acid sequence for Streptavidin is described in Argarana et al., Nucl. AcidRes. 14:1871-1882, 1986. Nucleic acid sequences are available, for example, as follows: chicken mRNA for avidin, Gene Bank Acc. No. X5343, Gore et al., Nucl. AcidRes. 15: 3595-3606, 1987; chicken, strain White Leghorn mRNA for avidin, Gene Bank Acc. No. L27818 streptavidin from Strep. avidinii, Gene Bank Acc. No. X03591, Argarana et al., Nucl. Acid Res.
14:1871-1882, 1986; synthetic gene for streptavidin from Strep. avidinii, Gene Bank Acc. No. A00743, Edwards, W089/03422; and synthetic gene for streptavidin, Gene Bank Acc. No. X65082, Thompson et al., Gene 136: 243-246, 1993.
Avidin and Streptavidin are preferably used in a tetrameric form, although monomers can be used. In reciting herein that an avidin or Streptavidin protein retains biotin-binding activity, it is of course envisioned that this may involve the protein forming multimeric associations with like proteins. Other useful members of a binding pair can include an antibody specific for a polypeptide or other molecule, any polypeptide to which an antibody is available or can be prepared, thioredoxin, which binds phenylarsine oxide (expression vectors include, for example, the thioredoxin fusion protein vector pTrxFus available from Invitrogen, Carlsbad, CA, or Invitrogen Netherlands), poly-His sequences that bind to divalent cations such as nickel II (expression vectors include, for example, the pThioHis vectors A, B and C available from Invitrogen), glutathione-Stransferase vectors that bind to glutathione (vector for example available from Pharmacia Biotech, Piscataway, NJ). Methods of producing such antibodies are available to those of ordinary skill in light of the ample description herein of polypeptide expression systems and of known antibody production methods. For antibody preparation methods, see, for WO 99/29838 PCT/US98/26086 WO 9929838PCT/US98/260R6 -9example, Ausubel et al., Short Protocols in Molecular Biology, John Wiley Sons, New York, 1992. The binding-pairs used in the invention preferably display high affinity binding even at relatively low pH, such as a pH of about 5. In some embodiments of the invention, the member of a binding pair that is attached to an enzyme is not limited to polypeptide members of binding pairs. In this case, biotin is the most preferred such member of a binding pair.
In many embodiments of the invention, the polypeptide chains making up the fusion proteins will be manufactured by recombinant means, as described further below.
These recombinant techniques allow for the polypeptide chains to be modified by amino acid substitutions and sequence deletions such as deletions of internal or terminal sequences. Further, the N-terminal leader sequence can be modified as appropriate to promote export of the protein from the host cell. Such modified recombinant products can be readily synthesized on a small pilot scale and tested, for instance for enzymatic activity or binding activity. These pilot tests can generally be conducted without strenuous purification procedures since the organism used to produce the recombinant substance can be selected to lack the relevant activity, allowing for crude lysates or unpurified culture medium to be tested for the activity.
Mutational and deletional approaches can be applied to all of the nucleic acid sequences encoding relevant polypeptide chains. Conservative mutations are preferred.
Such conservative mutations include mutations that switch one amino acid for another within one of the following groups: 1. Small aliphatic, nonpolar or slightly polar residues: Ala, Ser, Thr, Pro and Gly; 2. Polar, negatively charged residues and their amides: Asp, Asn, Glu and Gln; 3. Polar, positively charged residues: His, Arg and Lys; 4. Large aliphatic, nonpolar residues: Met, Leu, Ile, Val and Cys; and Aromatic residues: Phe, Tyr and Trp.
A preferred listing of conservative variations is the following: Original Residue Variation Ala Gly, Ser Arg Lys WO 99/29838 PCT/US98/26086 Asn Gin, His Asp Glu Cys Ser Gin Asn Glu Asp Gly Ala, Pro His Asn, Gin Ile Leu, Val Leu Ile, Val Lys Arg, Gin, Glu Met Leu, Tyr, Ile Phe Met, Leu, Tyr Ser Thr Thr Ser Trp Tyr Tyr Trp, Phe Val lie, Leu The types of variations selected may be based on the analysis of the frequencies of amino acid variations between homologous proteins of different species developed by Schulz et al., Principles of Protein Structure, Springer-Verlag, 1978, on the analyses of structureforming potentials developed by Chou and Fasman, Biochemistry 13, 211, 1974 and Adv.
Enzymol, 47, 45-149, 1978, and on the analysis of hydrophobicity patterns in proteins developed by Eisenberg et al., Proc. Natl. Acad. Sci. USA 81, 140-144, 1984; Kyte Doolittle; J. Molec. Biol. 157, 105-132, 1981, and Goldman et al., Ann. Rev. Biophys.
Chem. 15, 321-353, 1986. All of the references of this paragraph are incorporated herein in their entirety by reference.
In a preferred embodiment of the invention, the association between the fibrinogen-converting enzyme or snake-derived proteinase and the polypeptide that is a member of a binding pair is effected by recombinantly expressing the two components of the fusion proteins with the two polypeptide encoding nucleic acids are directly fused such that in the synthesized protein the C-terminal amino acid of one polypeptide is directly linked by a peptide bond to the N-terminal amino acid of the other or the two polypeptide encoding nucleic acids are fused via a linker nucleic acid encoding an amino acid or polypeptide, such that in the synthesized protein the C-terminal amino acid of one polypeptide is linked by a peptide bond to the N-terminal of the linker amino acid or WO 99/29838 PCT/US98/2fi086 11 polypeptide, which linker amino acid or polypeptide is linked by a peptide bond at its Cterminal to the N-terminal of the other polypeptide of the fusion protein.
In other embodiments, the fusion between the fibrinogen-converting enzyme or snake-derived proteinase and the polypeptide that is a member of a binding pair is effected by other types of bonds including disulfide bonds between cysteine residues of the respective polypeptides, amide bonds between amine and carboxylate functionalities of the two polypeptides, and bonds formed by bifunctional crosslinking reagents. Such bifunctional reagents include compounds with activated acyl esters such as Nhydroxysuccinimide esters, mercuric ion, other mercury compounds, compounds containing maleimide functionalities, compounds containing iodoacetyl functionalities, compounds containing fluoro-nitro-aryl functionalities, compounds containing alkylimidate functionalities, compounds containing arylsulfonyl chloride functionalities, compounds containing isocyanate functionalities, aldehyde or dialdehyde compounds and compounds containing diazoaryl functionalities. Crosslinking methods using such reagents are reviewed in Means and Feeney, Chemical Modification of Proteins, Holden- Day, San Francisco, 1971, which document is incorporated herein in its entirety by reference.
Among the modifications that can be added to a protein by recombinant methods are sequences that are glycosylated when the protein is expressed in an appropriate cell.
N-linked glycosylations typically occur at the asparagine of Asn-Xaa-Ser/Thr tripeptide subsequences of glycoproteins.
Converting Enzyme-Attachable Polypeptide Fusion Protein In one embodiment of the invention, the fibrinogen converting enzyme is fused not with the member of a binding pair, but with a polypeptide designed to facilitate linkage with a member of a binding pair. Such a facilatitive polypeptide can, for instance, comprise a polylysyl polypeptide, or another repetitive polypeptide that is rich in an amino acid whose side chain is useful in linking the member of a binding pair. Preferably, the facilitative polypeptide comprises between about 10 and about 50 amino acid residues, more preferably between about 20 and about 30 amino acid residues. Preferably, the linkable amino acid comprises lysine, arginine, histidine, aspartic acid, glutamic acid or cysteine, more preferably lysine or cysteine, and yet more preferably lysine. For methods on how to link biotin to the facilatitive polypeptide can be found, for example, in Savage WO 99/29838 12et al., Avidin. Biotin Chemistry: A Handbook, Pierce Chemical Co., 1992. A preferred method of linking a member of a binding pair to a carbohydrate structure is oxidation with periodate followed by reductive alkylation.
Recombinant Nucleic Acids, Cells and Methods Where nucleic acid sequence is known, or sufficient amino acid sequence is known to predict useful primers, nucleic acid amplification methods, such as polymerase chain reaction (PCR) methods, can be used to amplify useful polypeptide-encoding nucleic acids from the RNA of a tissue that expresses such a polypeptide. Such PCR methods are well described in PCR Protocols, Cold Spring Harbor Press, 1991. In some cases, PCR methods directly applied will only isolate internal sequences. Fortunately, methods have been developed to amplify and isolate sequences extended from such internal sequences so as to encompass all useful sequence. One such method is referred to as PCR-RACE, and protocols for this method are available, for example, from Gibco BRL (Gaithersburg, MD). Where amplification methods can be used to isolate two or more overlapping nucleic acids that together encode all of the needed nucleic acid, these can be pieced together using natural restriction sites or by designing restriction sites by use of appropriate PCR primers. Where restriction sites are designed into the PCR primers, it can be necessary to change the codons used to encode particular amino acid residues or to make mutational changes (preferably conservative) to design the restriction site. In some cases, it may be necessary to subclone a particular nucleic acid fragment and use wellestablished site directed mutagenesis techniques to engineer the needed restriction sites.
See, Ausubel et al, Current Protocols in Molecular Biology, John Wiley and Sons, New York, 1995, pp.8.1.1-8.1.6.
To construct non-naturally occurring enzyme- or binding polypeptide-encoding nucleic acids, the native sequences can be used as a starting point and modified to suit particular needs. For instance, the sequences can be mutated to incorporate useful restriction sites. See Maniatis et al. Molecular Cloning, a Laboratory Manual (Cold Spring Harbor Press, 1989). Such restriction sites can be used to create "cassettes", or regions of nucleic acid sequence that are facilely substituted using restriction enzymes and ligation reactions. The cassettes can be used to substitute synthetic sequences encoding mutated enzyme or binding polypeptide amino acid sequences. Alternatively, the enzyme or binding polypeptide-encoding sequence can be substantially or fully synthetic. See, for WO 99/29838 PCT[US98/26086 13 example, Goeddel et al., Proc. Natl. Acad. Sci. USA, 76, 106-110, 1979. For recombinant expression purposes, codon usage preferences for the organism in which such a nucleic acid is to be expressed are advantageously considered in designing a synthetic enzyme or binding polypeptide-encoding nucleic acid. For example, a nucleic acid sequence incorporating prokaryotic codon preferences can be designed from a mammalian-derived sequence using a software program such as Oligo-4, available from National Biosciences, Inc. (Plymouth, MN).
The nucleic acid sequence embodiments of the invention are preferably deoxyribonucleic acid sequences, preferably double-stranded deoxyribonucleic acid sequences. However, they can also be ribonucleic acid sequences.
Numerous methods are known to delete sequence from or mutate nucleic acid sequences that encode a protein.and to confirm the function of the proteins encoded by these deleted or mutated sequences. Accordingly, the invention also relates to a mutated or deleted version of a nucleic acid sequence that encodes a protein that retains the ability to bind specifically another molecule or the intended enzymatic activity. These analogs can have N-terminal, C-terminal or internal deletions, so long as appropriate function is retained.
A suitable expression vector is capable of fostering expression of the included polypeptide in a host cell, which can be eukaryotic (including fungal), or prokaryotic.
Useful expression vectors include pRc/CMV (Invitrogen, San Diego, CA), pRc/RSV (Invitrogen), pcDNA3 (Invitrogen), Zap Express Vector (Stratagene Cloning Systems, LaJolla, CA); pBk/CMV or pBk-RSV vectors (Stratagene), Bluescript II SK Phagemid Vectors (Stratagene), LacSwitch (Stratagene), pMAM and pMAM neo (Clontech, Palo Alto, CA), pKSVIO (Pharmacia, Piscataway, NJ), pCRscript (Stratagene) and pCR2.1 (Invitrogen), among others. Useful yeast expression systems include, for example, pYEUra3 (Clontech). Useful baculovirus vectors, for expression in insect cells, include several viral vectors from Invitrogen (San Diego, CA) such as pVL1393, pVL1392, pBluBac2, pBluBacHis A, B or C, and pbacPAC6 from Clontech. Some of these vectors will utilize inducible promoters such as the lac promoter. In one aspect of the invention, inducible promoters are desirable, such as promoters responsive to zinc or other metal ions, to metabolites or metabolite mimics such as isopropylthio- -galactoside, or to hormones such as estrogen or ecdyson (for instance, found in expression systems WO 99/29838 PCTIUS98/26086 -14available from Invitrogen, San Diego, CA). Inducible systems help to minimize the adverse effects that can flow from the expressed protein having toxic effects on the expression cells.
In one embodiment of the invention, the polypeptides are preferably expressed in a mammalian cell line, preferably a transformed cell line with an established cell culture history. In this embodiment, suitable cell lines include COS-1, COS-7, LM(tk-), HeLa, HEK293, CHO, Rat-1 and NIH3T3.
In another embodiment, the polypeptides are expressed in a cell line that is more inexpensively maintained and grown than are mammalian cell lines, such as a bacterial cell line or a fungal cell line such as a yeast cell line. In this aspect of the invention, E. coli bacterial cells are particularly preferred.
In all aspects of recombinant methodology referred to herein, ample guidance can be found in a number of widely recognized authorities including: Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Press, 1989; and Ausubel et al., Short Protocols in Molecular Biology, John Wiley Sons, New York, 1992.
Methods of Producing Recombinant Fusion Proteins One simplified method of isolating polypeptides synthesized by an organism under the direction of one of the nucleic acids of the invention is to recombinantly express a version of the fusion protein having a fusion component that is facilely affinity purified.
This fusion component can be simply the polypeptide chain that is a member of a binding pair. Or, this fusion component can be another fused polypeptide. A useful component for purification is, for instance, glutathione S-transferase, which is encoded on commercial expression vectors vector pGEX4T3, available from Pharmacia, Piscataway, NJ).
Another useful purification component is, for instance, thioredoxin. This glutathione S-transferase-containing fusion protein can then be purified on a glutathione affinity column (for instance, that available from Pharmacia, Piscataway, New Jersey). If extra fusion partners are used, the extra fusion partner can be removed by partial proteolytic digestion approaches that preferentially attack unstructured regions such as the linkers between the extra fusion partner and the desired fusion protein. The linkers can be designed to lack structure, for instance using the rules for secondary structure forming WO 99/29838 PCT/US98/26086 potential developed, for instance, by Chou and Fasman, Biochemistry 13, 211, 1974 and Chou and Fasman, Adv. in Enzymol. 47, 45-147, 1978. The linker can also be designed to incorporate protease target amino acids, such as, arginine and lysine residues, the amino acids that define the sites cleaved by trypsin. To create the linkers, standard synthetic approaches for making oligonucleotides can be employed together with standard subcloning methodologies. Other fusion partners besides GST can be used. Procedures that utilize eukaryotic cells, particularly mammalian cells, are preferred since these cells will post-translationally modify the protein to create molecules highly similar to or identical to native proteins.
Additional purification techniques can be applied, including without limitation, preparative electrophoresis, FPLC (Pharmacia, Uppsala, Sweden), HPLC using gel filtration, reverse-phase or mildly hydrophobic columns), gel filtration, differential precipitation (for instance, "salting out" precipitations), ion-exchange chromatography and affinity chromatography.
Preferably, the protein is substantially pure, meaning a purity of at least 20% w/w with respect to other proteins, more preferably at least about 50%, yet more preferably at least about 70%, still more preferably at least about 90%. For the purposes of this application, the fusion protein is "isolated" if it has been separated from other proteins or other macromolecules of the cell or tissue from which it is derived or prepared.
Methods of Preparing Fibrin Compositions In using the fusion protein of the invention, blood is for example drawn from a patient and mixed with an anticoagulant, such as trisodium citrate to a final concentration of about 0.5% w/v. Blood and liver cell cultures, recombinant cultures or milk from transgenically modified mammals are examples of suitable sources of fibrinogen. Plasma is isolated by centrifugation, which removes the cellular components of the blood. The fusion protein is added to the fibrinogen containing solution, for example, at a concentration approximately corresponding, on a molar basis, to a concentration of baxtroxobin of about 0.1 ug/ml to about 100 pg/ml, preferably to a concentration of about 0.5 pg/ml to about 50 pg/ml. A precipitate of fibrin polymer forms from the reaction of fibrinogen with enzyme incorporated into the fusion protein. Where that fibrinogen-converting enzyme is batroxobin, the polymer is generally made up of fibrin I.
The fibrin polymer is isolated by centrifugation or filtration, and then dissolved in a low WO 99/29838 PCT7US98/26086 16pH buffer, such as 0.2 M sodium acetate, pH 4.0, preferably in the presence of calcium ions, for example at a concentration of about 20 mM. Biotin covalently bound to a solid support such as agarose is added in sufficient quantity to bind in excess of about 99% of the fusion protein. The biotinylated support can be prepared, for example, by reacting one of the biotinylating agents available from Boehringer Manheim (Indianapolis, IN) or Clontech (Palo Alto, CA) with a solid support having primary amino groups. The biotinylating reagents typically have a biotinyl substituent, one to two aminocaproyl spacer groups, and a reactive N-hydroxysuccinimide group. The solid support can be, for example, the amino-derivatized agarose resins available from Sigma (St. Louis, MO) or an amino-derivatized chromatography matrix available from Pharmacia (Uppsala, Sweden).
The solubilized fibrin is removed from the support-bound fusion protein by centrifugation or filtration. The solubilized fibrin is now ready for use in a sealant, for instance as described in Edwardson et al., European Patent Application No. 592,242.
Preparation of Solid Supports The solid support to which the second member of the binding pair is bound is, for example made up of beaded or non-beaded particles of carbohydrate-based material such as agarose, cross-linked agarose or cross-linked dextran, or a non-porous material such as polystyrene. Methods for covalently coupling molecules to solid supports are well known in the art, and include for example creating reactive sites on the solid supports with cyanogen bromide or reacting the solid supports with bifunctional reagents such as diglycidyl ethers. See, for example, "Attachment to Solid Supports" in Means and Feeney, Chemical Modification of Proteins, Holden-Day, San Francisco, 1971, pp. 40-43 or Affinity Chromatography: A Practical Approach, Dean et al., eds., IRL Press, Oxford, 1991, the disclosures of which two references are incorporated herein in there entirety by reference. For coupling with silica-based materials, alkyloxysilane moieties, for example, can provide the silica-reactive moiety of a bifunctional coupling reagent. For example, y-glycidoxypropyltrimethoxysilane can be reacted with the silica-based material, which is then directly reacted with the protein (via the glycidic ether moiety), or a second step is employed such as reacting the glycidic ether with an amine and subsequently attaching by reductive alkylation a glycoprotein that is mildly oxidized (for instance with periodate) to contain aldehyde moieties. A preferred coupling chemistry reacts a carbohydrate-based solid support with a hydrazide group, and then coupling by reductive WO 99/29838 PCT/US98/26086 17alkylation a glycoprotein that is mildly oxidized (for instance with periodate) to contain aldehyde moieties. See, Axelsson et al., Thromb. Haemost. 36: 517, 1976, which document is incorporated herein in its entirety by reference.
The following examples further illustrate the present invention, but of course, should not be construed as in any way limiting its scope.
Example IA Mammalian Vector Encoding Batroxobin A EcoRT-XbaI fragment encoding batroxobin is excised from a pUC 18 clone (R&D Systems, Inc., Minneapolis, MN) and cloned into the multiple cloning site of pCIneo (Promega, Southampton, UK). The expression sequence is made up of the -24 to 228 sequence of batroxobin which includes the leader sequence. The batroxobin enzyme is expressed in CHO cells from the resulting vector.
Example 1B Bacterial Vector Encoding Batroxobin-thioreductase fusion Protein A BsaI-XbaI fragment encoding batroxobin was excised from a pCI/neo clone (R&D Systems, Inc., Minneapolis, MN) and cloned into the multiple cloning site of pTrxFus (Invitrogen). The resulting fusion protein expressed in E. coli was made up of thioredoxin fused at its 5' end via linker with an enterokinase cleavage site to the 1 to 228 amino acid sequence of batroxobin. The fusion protein was purified phenylarsine oxide column (Invitrogen, Netherlands).
Example 2 Chemical Formation of a Batroxobin-Avidin Fusion Protein Covalent complexes may be formed between batroxobin and avidin using N-succinimidy-3-(2-pyridyldithio)proprionate (SPDP, Pierce Chemical Co., Rockford, IL) as follows: 3mg of batroxobin was reacted with 1.9 mg SPDP dissolved in 0.75 ml ethanol for 60 minutes at room temperature. 6 mg avidin was reacted identically in a separate container. The protein product of each reaction was separately desalted on Sephadex G25 in 50 mM sodium phosphate, 20 mM NaCl, pH 7.0 buffer. The derivatised proteins were then activated by reduction, which exposed thiol groups derived from the SPDP, mixed together, and the mixed proteins were again desalted by gel filtration on Sephadex G25. Batroxobin-avidin conjugates were isolated (away from nonconjugated protein) by gel filtration on Sephadex G100.
Sequence Listing WO 99/29838 PCTIUS98/26086 -18- SEQ ID NO: 1 is of the Gallus galhts cDNA for avidin, and SEQ ID NO:2 is the corresponding protein. Amino acids 1-24 are believed to be the leader sequence, and amino acids 25-152 the mature protein. SEQ ID NO:3 is an cDNA for streptavidin, and SEQ ID NO:4 is the corresponding protein. Amino acids 1-24 are believed to be the leader sequence, and amino acids 25-183 the mature protein. SEQ ID NO:5 is of the Bothrops atrox cDNA for batroxobin, and SEQ ID NO:6 is the corresponding protein.
Amino acids 1-18 are believed to be the leader sequence, and amino acids 25-255 the mature protein.
All publications and references, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference in their entirety as if each individual publication or reference were specifically and individually indicated to be incorporated by reference herein as being fully set forth. Any patent application to which this application claims priority is also incorporated by reference herein in its entirety in the manner described above for publications and references.
While this invention has been described with an emphasis upon preferred embodiments, it will be obvious to those of ordinary skill in the art that variations in the preferred devices and methods may be used and that it is intended that the invention may be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications encompassed within the spirit and scope of the invention as defined by the claims that follow.
EDITORIAL NOTE 19058/99 SEQUENCE LISTING PAGES Al TO A5 FOLLOW PAGE 18 OF THE
DESCRIPTION.
WO 99/29838 PCT/US98/26086 A- 1 SEQUENCE LISTING <110> Bristol-Myers Squibb Company Stewart A. Cederhom-Williams <120> Fibrinogen-Converting Enzyme Hybrids <130> CV0268 <150> 60/067,978 <151> 1997-12-09 <160> 6 <170> FastSEQ for Windows Version <210> 1 <211> 459 <212> DNA <213> Gallus gallus <220> <221> CDS <222> (456) <400> 1 atg gtg cac gca acc tcc ccg ctg ctg ctg ctg ctg ctg ctc agc ctg 48 Met Val His Ala Thr Ser Pro Leu Leu Leu Leu Leu Leu Leu Ser Leu 1 5 10 gct ctg gtg gct ccc ggc ctc tct gcc aga aag tgc tcg ctg act ggg 96 Ala Leu Val Ala Pro Gly Leu Ser Ala Arg Lys Cys Ser Leu Thr Gly 25 aaa tgg acc aac gat ctg ggc tcc aac atg acc atc ggg gct gtg aac 144 Lys Trp Thr Asn Asp Leu Gly Ser Asn Met Thr Ile Gly Ala Val Asn 40 agc aga ggt gaa ttc aca ggc acc tac atc aca gcc gta aca gcc aca 192 Ser Arg Gly Glu Phe Thr Gly Thr Tyr Ile Thr Ala Val Thr Ala Thr 55 tca aat gag atc aaa gag tca cca ctg cat ggg aca caa aac acc atc 240 Ser Asn Glu Ile Lys Glu Ser Pro Leu His Gly Thr Gln Asn Thr Ile 70 75 aac aag agg acc cag ccc acc ttt ggc ttc acc gtc aat tgg aag ttt 288 Asn Lys Arg Thr Gln Pro Thr Phe Gly Phe Thr Val Asn Trp Lys Phe 90 tca gag tcc acc act gtc ttc acg ggc cag tgc ttc ata gac agg aat 336 Ser Glu Ser Thr Thr Val Phe Thr Gly Gln Cys Phe Ile Asp Arg Asn 100 105 110 ggg aag gag gtc ctg aag acc atg tgg ctg ctg cgg tca agt gtt aat 384 Gly Lys Glu Val Leu Lys Thr Met Trp Leu Leu Arg Ser Ser Val Asn 115 120 125 gac att ggt gat gac tgg aaa gct acc agg gtc ggc atc aac atc ttc 432 Asp Ile Gly Asp Asp Trp Lys Ala Thr Arg Val Gly Ile Asn Ile Phe 130 135 140 WO 99/29838
A-
ict cgc ctg cgc aca cag aag gag tga Phr Arg Leu Arg Thr Gin Lys Glu 145 150 PCTIUS98/26086 .2 459 Met Al a Lys Ser Ser As n Ser Gly Asp Thr 145 <210> 2 <211> 1 <212> P <213> G <400> 2 Val His A Leu Vai A 2 Trp Thr A Arg Gly G Asn Glu I Lys Arg T Glu Ser T 1 Lys Glu V 115 Ile Gly A 130 Arg Leu A la la 0 sn lu ie hr hr 00 al sp rg Thr Pro Asp Phe Lys Gin Thr Leu Asp Thr 52
RT
alius galius Ser Gi y Leu Thr Glu 70 Pro Val Lys T rp Gin 150 Pro Leu Gly G1 y 55 Ser Thr Phe Thr Lys 135 Lys Leu Ser Ser Thr Pro Phe Thr Met 120 Al a Glu Leu Al a As n Tyr Leu Gly Gi y 105 T rp Thr Leu Arg Met Ile His Phe 90 Gin Leu Arg Leu Lys Thr Thr Gi y 75 Thr Cys Leu Val Leu Cys Ile Al a Thr Val Phe Ar g Gi y 140 Ser Thr Val1 Al a Thr Lys Arg Val Ile Leu Gi y As n Thr Ile Phe As n As n Phe <210> 3 <211> 5~ <212> D] <213> S~ <220> <221> Cl <222>( <400> 3 cgc aag a' Arg Lys I.
52 treptococcus
DS
1) (549) atg Met 1 tcg Ser tc gtc le Val 5 gtt gca gcc atc Val Ala Ala Ile gtt tcc ctg acc Val Ser Leu Thr acg gtc Thr Val aag gcc Lys Ala att acg gcc Ile Thr Ala agc Ser gct tcg gca Ala Ser Ala tcc aag gac Ser Lys Asp cag gtc tcg Gin Val Ser ctc ggc tcg Leu Gly Ser gga. acc tac Gly Thr Tyr gcc Al a gcc gag gc Ala Giu Ala ggC Gly 40 acc ggc acc Thr Gly Thr tgg T rp tac aac cag Tyr Asn Gin acc ttc atc Thr Phe Ile gag tcg gcc Giu Ser Ala gtg Val 55 gtc Val1 acc gcg ggc gcc Thr Ala Gly Ala gac Asp ggc gcc ctg acc Gly Ala Leu Thr 144 192 240 ggc aac gcc Gly Asn Ala agc cgc tac gtc Ser Arg Tyr Vai WO 99/29838 WO 9929838PCT/US98/26086 A- 3 acc ggt cgt tac Thr Gly Arg Tyr ga c Asp agc gcc ccg gcc Ser Ala Pro Ala acc Thr 90 aac As n gac ggc agc ggc Asp Gly Ser Gly acc gcc Thr Ala ctc ggt tgg Leu Gly Trp gcg acc acg Ala Thr Thr 115 aac acc cag Asn Thr Gin gtg gcc tgg aag Val Ala Trp Lys aat As n 105 gtc Val1 tac cgc aac Tyr Arg Asn agc ggc cag Ser Gly Gin tac Tyr 120 tcc Ser ggc ggc gcc Gly Gly Ala gag Gi u 125 gcc Al a gcc cac tcc Ala His Ser 110 gcg agg atc Ala Arg Ile aac gcc tgg Asn Ala Trp 288 336 384 432 480 528 tgg ctg ctg Trp Leu Leu ggc acc aco Gly Thr Thr 130 aag tcc Lys Ser acg Ctg gtc Thr Leu Val gac acc ttc Asp Thr Phe 145 gc Al a acc Thr 155 gg c Gly aaq gtg aag ccg Lys Vai Lys Pro tcc Ser 160 aac As n gcc too atc Ala Ser Ile gac Asp 165 gcg aag aag Ala Lys Lys gc Al a 170 gto aac aac Val Asn Asn ggo Gly 175 cog oto gao Pro Leu Asp gco Al a 180 gtt cag cag tag Val Gin Gin Met Ser Gin Leu Gi y Thr Leu Al a As n Lys 145 Al a Pro <210> 4 <211> 1 <212> P: <213> S* <400> 4 Arg Lys I Ile Thr A 2 Val Ser A Gly Ser T Thr Tyr G Gly Arg T Gly Trp T 1 Thr Thr T 115 Thr Gin T 130 Ser Thr L Ala Ser I Leu Asp A 1 <210> 83
RT
treptococcus le la 0 la hr lu yr hr 00 rp rp eu le .1a Val1 Al a Gi u Ile Al a 70 Ser Al a Gly Leu Gly 150 Al a Gin Ala Ser Al a Val 55 Val1 Al a T rp Gin Th r 135 His Al a Gin Ala Ile Ala Val Ser Leu Thr Thr Val Al a Gi y Thr Gly Pro Lys Tyr 120 Ser Asp Lys Asp Ile Al a As n Al a As n 105 Val1 Gly Thr Lys Pro Thr Gly Al a Thr As n Gly Th r Phe Al a 170 Ser Gly Al a Glu 75 Asp Tyr Gly Thr Th r 155 Gi y Lys Thr Asp Ser Gi y Arg Al a Glu 140 Lys Val1 Lys As n Leu Val Thr His Arg Al a Pro Gly 175 Al a Gin Thr Leu Al a Ser Ile T rp Ser 160 As n WO 99/29838 <211> 768 <212> DNA <213> Bat] <220> <221> CDS <222> (1) <400> atg gtg ctg atc Met Val Leu Ile 1 tac gca caa aag Tyr Ala Gin Lys ata aat gaa cat Ile Asn Giu His ttc tgt ggt atg Phe Cys Gly Met cac tgt aac agg His Cys Asn Arg agt gta gca aat Ser Val Ala Asn att tgt ccc aat Ile Cys Pro Asn 100 ttg atc agg ctg Leu Ile Arg Leu 115 ctc agc ttg cct Leu Ser Leu Pro 130 atg gga tgg ggc Met Gly Trp Giy 145 cct cat tgt gct Pro His Cys Ala gct tac aat ggg Ala Tyr Asn Gly 180 gga ggc ata gat Gly Gly Ile Asp 195 aat gga caa ttc PCT/US98/26086 A-4 rirops atrox (765) aga gtg Arg Val 5 tct tct Ser Ser cct ttc Pro Phe act ttg Thr Leu aga ttt Arg Phe 70 tat gat Tyr Asp aag aaa Lys Lys gac aga Asp Arg tcc aac Ser Asn gca atc Ala Ile 150 aac att Asn Ile 165 ttq ccg Leu Pro aca tgt Thr Cys cag ggc ata Ile gaa Giu ctt Leu atc Ile 55 atg Met gag Giu aaa Lys c ct Pro cct Pro 135 a ca Thr aac As n g cg Al a ggg Gi y att g ca Al a ctg Leu gca Al a 40 aa c As n cgc Arg gtg Val aat As n gtc Val 120 ccc Pro act Th r ctg Leu aaa Lys ggt Gly 200 tta aac Asni gt c Val1 ttc Phe cag Gin ata Ile gta Vali gtc Val1 105 aaa Lys agt Ser tct Ser ttc Phe aca Thr 185 ga c Asp t ct ctt Leu 10 att Ile atg Met gaa Gi u cac His a ga Arg 90 ata Ile aac As n gtg Val gaa Giu aat As n 170 ttg Leu t ct Ser tgg ctg Leu gga Gly tac Tyr tgg T rp ctt Leu 75 tac Tyr a cg Thr agt Ser ggc Gl y gac Asp 155 aat As n t gt Cys ggg Gi y gga ata Ile ggt Gi y tac Tyr gtg Val1 ggt Gi y cca Pro ga c Asp gaa Giu t ca Ser 140 act Thr acg Th r gca Al a gga Giy agt tta Leu gat Asp tct Ser ctg Leu aaa Lys aag Lys aag Lys cac His 125 gtt Vali tat Tyr gtg Val ggt Gi y ccc Pro 205 gat gtt Val tgt Cys cgg Arg gct Al a gcc Al a aag Lys att Ile gcg Al a cgt Arg gat Asp cgt Arg 175 ct g Leu atc Ile tgt t ct Ser ga c Asp tat Tyr gca Al a gga Gi y ttc Phe atg Met cct Pro att Ile gtc Val1 160 gaa Gi u caa Gin tgt Cys gcc 48 96 144 192 240 288 336 384 432 480 528 576 624 672 WO 99/29838 WO 9929838PCT/US98/26086 A Asn Gly Gin Phe Gin Gly Ile Leu Ser 210 215 gaa ccg cgt aag cct gcc ttc tac acc Giu Pro Arg Lys Pro Ala Phe Tyr Thr 225 230 tgg atc cag agc att att gca gga aat Trp Ile Gin Ser Ile Ile Ala Gly Asn 245 Trp Gly Ser Asp Pro Cys Ala 220 aag qtc ttt gat tat ctt ccc Lys Val Phe Asp Tyr Leu Pro 235 240 aaa act gcg act tgc ccg Lys Thr Ala Thr Cys Pro 250 255 720 765 768 Met Tyr Ile Phe His Ser Ile Leu Leu Met 145 Pro Al a Gly As n Giu 225 <210> 6 <211> 2 <212> P <213> B <400> 6 Val Leu I.
Ala Gin L 2 Asn Glu H.
Cys Gly M Cys Asn A Val Ala A Cys Pro A 1 Ile Arg L 115 Ser Leu P 130 Gly Trp G His Cys A Tyr Asn G 1 Gly Ile A 195 Gly Gin P 210 Pro Arg L
RT
othrops atrox le ys 0 is et rg sn sn 00 eu ro la ly 80 sp he ys Arg Ser Pro Th r Arg Tyr Lys Asp Ser Al a As n 165 Leu Thr Gin Pro Val1 Ser Phe Leu Phe 70 Asp Lys Arg As n Ile 150 Ile Pro Cys Gi y Al a 230 Ile Glu Leu Ile 55 Met Giu Lys Pro Pro 135 Thr As n Al a Gi y Ile 215 Phe Ala Asn 'Leu Leu Ile Leu Gin Val Ser 10 Leu Al a 40 As n Arg Val As n Val1 120 Pro Thr Leu Lys Gly 200 Leu Tyr Val1 25 Phe Gin Ile Val Val1 105 Lys Ser Ser Phe Thr 185 Asp Ser Thr Ile Met Gi u His Arg Ile As n Val Glu As n 170 Leu Ser T rp Lys Gi y Tyr T rp Leu 75 Tyr Thr Ser Gi y Asp 155 As n Cys Gi y Gly Val 235 Gly Tyr Val1 Gly Pro Asp Glu Ser 140 Thr Thr Al a Gi y Ser 220 Phe Asp Ser Leu Lys Lys Lys His 125 Val Tyr Val Gly Pro 205 Asp Asp Glu Pro Thr His Giu Asp 110 Ile Cys Pro Cys Val 190 Leu Pro Tyr Asp Tyr Al a Gi y Phe Met Pro Ile Val 160 Gi u Gin Cys Al a Pro 240 Trp Ile Gin Ser Ile Ile Ala Gly Asn Lys Thr Ala Thr Cys 245 250

Claims (16)

1. A multidomain protein comprising: a first polypeptide chain comprising a fibrinogen-converting enzyme; and a second polypeptide chain comprising an avidin or Streptavidin polypeptide effective to bind biotin; wherein the first polypeptide chain and the second polypeptide chain are part of a continuous polypeptide chain.
2. A multidomain protein of claim 1, wherein the second polypeptide chain comprises at least two biotin binding sites.
3. A multidomain protein of claims 1 or 2 wherein the second polypeptide chain is associated with the first polypeptide chain by binding to a biotin molecule covalently linked to the first polypeptide chain.
4. A multidomain protein according to claims 1 or 2, wherein the first and second polypeptides are fused directly via a peptide bond or fused via a linker polypeptide chain. The multidomain protein of any one of claims 1 to 4, wherein the first polypeptide chain comprises a snake venom enzyme.
6. The multidomain protein of claim 5, wherein the first polypeptide chain comprises a venom enzyme from Agkistrodon acutus, Agkistrodon contortrix 20 contortrix, Agkistrodon halys pallas, Agkistrodon (Calloselasma) rhodostama, Bothrops asper, Bothrops atrox, Bothrops insularis, Bothrops jararaca, Bothrops Moogeni, Lachesis muta muta, Crotalus adamanteus, Crotalus durissus terrificus, Trimerseurus flavorviridis, Trimeresurus gramineus or Bitis gabonica.
7. A multidomain protein according to any one of claims 1 to 6, wherein the second polypeptide chain is an avidin peptide effective to bind biotin.
8. A multidomain protein according to any one of claims 1 to 7, wherein the second polypeptide chain is a Streptavidin peptide effective to bind biotin.
9. A multidomain protein substantially as hereinbefore described with reference to the examples. 30 10. A multidomain protein substantially as hereinbefore described as illustrated in any one of SEQ ID NOS: 2, 4 or 6.
11. A multidomain protein according to any one of claims 1 to 10 which is a recombinant fusion protein. retypedcdaims8.8-02.doCN:IRN\617493,etypeddaims--2.doc
12. A nucleic acid which encodes a recombinant fusion protein as defined in claim 11.
13. A vector comprising the nucleic acid of claim 12 and sufficient regulatory sequences for expressing the fusion protein in a cell.
14. A cell comprising the vector of claim 13. A method of producing a recombinant fusion protein of claim 11 comprising the steps of: growing the cell of claim 14 in a culture medium; and recovering from the cell or the culture medium the fusion protein.
16. A fusion protein formed by the method of claim
17. A method of preparing a fibrin composition, the method comprising contacting a composition comprising fibrinogen with a multidomain protein as defined by any one of claims 1 to 11.
18. A method according to claim 17 wherein a monomeric fibrin composition is formed.
19. A method according to claim 18, wherein the monomeric fibrin composition is contacted with a solid support. A method according to claim 19, wherein the solid support is removed thereby recovering a resulting monomeric fibrin composition. 20 21. A fibrin composition produced by the method of any one of claims 17 to DATED: 21 August 2002 •PHILLIPS ORMONDE FITZPATRICK Attorneys for: BRISTOL-MYERS SQUIBB COMPANY a. a0 .0a retypedcaims6-8-02dcN:IRN\67493Vretypedcaims-8-02.doc
AU19058/99A 1997-12-09 1998-12-09 Fibrinogen-converting enzyme hybrids Ceased AU753458B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6797897P 1997-12-09 1997-12-09
US60/067978 1997-12-09
PCT/US1998/026086 WO1999029838A1 (en) 1997-12-09 1998-12-09 Fibrinogen-converting enzyme hybrids

Publications (2)

Publication Number Publication Date
AU1905899A AU1905899A (en) 1999-06-28
AU753458B2 true AU753458B2 (en) 2002-10-17

Family

ID=22079665

Family Applications (1)

Application Number Title Priority Date Filing Date
AU19058/99A Ceased AU753458B2 (en) 1997-12-09 1998-12-09 Fibrinogen-converting enzyme hybrids

Country Status (6)

Country Link
EP (1) EP1037969A4 (en)
JP (1) JP2001526027A (en)
AU (1) AU753458B2 (en)
CA (1) CA2312476A1 (en)
NO (1) NO20002937L (en)
WO (1) WO1999029838A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6261820B1 (en) * 1999-10-01 2001-07-17 Amgen Inc. Fibronolytically active polypeptide
CN100494366C (en) * 2006-10-19 2009-06-03 康辰医药股份有限公司 Thrombin
DE102014112212A1 (en) 2014-08-26 2016-03-03 Akesion Gmbh Recombinant fusion proteins for the prevention or treatment of adhesions in tissues or organs

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0592242A1 (en) * 1992-10-08 1994-04-13 E.R. Squibb & Sons, Inc. Fibrin sealant compositions and method for utilizing same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6551794B1 (en) * 1995-11-09 2003-04-22 E. R. Squibb & Sons, Inc. Stable biotinylated biomolecule composition
US5691152A (en) * 1995-11-09 1997-11-25 E. R. Squibb & Sons, Inc. Stable avidin composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0592242A1 (en) * 1992-10-08 1994-04-13 E.R. Squibb & Sons, Inc. Fibrin sealant compositions and method for utilizing same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCOPES ET AL. PROTEIN PURIFICATION. PRINC & PRACT ED 3 1994 P 187 *

Also Published As

Publication number Publication date
NO20002937D0 (en) 2000-06-08
EP1037969A4 (en) 2003-05-21
EP1037969A1 (en) 2000-09-27
NO20002937L (en) 2000-08-08
JP2001526027A (en) 2001-12-18
CA2312476A1 (en) 1999-06-17
WO1999029838A1 (en) 1999-06-17
AU1905899A (en) 1999-06-28

Similar Documents

Publication Publication Date Title
Bach et al. Human tissue factor contains thioester-linked palmitate and stearate on the cytoplasmic half-cystine
Beintema et al. Amino acid sequence of the nonsecretory ribonuclease of human urine
US7833978B2 (en) Thrombomodulin derivatives and conjugates
JP3863579B2 (en) Method for obtaining insulin with correctly linked cystine bridges
US20130017591A1 (en) Method for the Preparation of Recombinant Human Thrombin and Fibrinogen
Clarke et al. The short loop between epidermal growth factor-like domains 4 and 5 is critical for human thrombomodulin function.
CA2254647C (en) Chimeric serine proteases
US6492494B1 (en) Method of making a fibrin sealant comprising alpha-2-antiplasmin
US20100159564A1 (en) Protease resistant recombinant bacterial collagenases
JPS62171699A (en) Production of protein
WO1996027027A1 (en) Improved method for purifying green fluorescent protein
AU753458B2 (en) Fibrinogen-converting enzyme hybrids
EP0528686B8 (en) Process for producing peptides
EP0781334A1 (en) Process for manufacture of a modified collagen-induced platelet aggregation inhibitor pallidipin
JP2002520044A (en) Soluble derivatives of anti-angiogenic peptides
WO1995018827A1 (en) Factor viii derivatives
Palen et al. Characterization of an enzyme that is capable of processing pro-gonadotropin-releasing hormone protein
WO2005081926A2 (en) Thrombomodulin derivatives and conjugates
CA2184334A1 (en) Anticoagulant factor va derivatives
CA2137779A1 (en) Purification of kringle containing proteins, and especially t-pa
JP2877253B2 (en) Method for selective cleavage of fusion protein
MXPA01011057A (en) Method of removing n-terminal alanine residues from polypeptides with aeromonas.
Strömqvist et al. Properties of recombinant human plasma procarboxypeptidase U produced in mammalian and insect cells
ODA et al. Purification and characterization of phospholipase A2 from Trimeresurus gramineus venom
WO1996027660A1 (en) Calcium-requiring, prothrombin-activating enzyme

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)